This article is a correction to:
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
Fangling Cheng1,2
Po Zhang1,2
Qungen Xiao1
Youwei Li1,2Minhai Dong1,2Heping Wang1Dong Kuang3,4Yue He1Qiuhong Duan5Feng Mao1Baofeng Wang1*
Dongsheng Guo1*- 1Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2Chinese-German Lab of Molecular Neuro-oncology of Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
- 3Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 4Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 5Department of Biochemistry and Molecular Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China
A Corrigendum on
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
by Cheng, F., Zhang, P., Xiao, Q., Li, Y., Dong, M., Wang, H., et al. (2019). Front. Oncol. 9:447. doi: 10.3389/fonc.2019.00447
In the original article, there was a mistake in Figure 4 as published. The second and third image in the first row of Figure 4A are the same. The corrected Figure 4 appears below.
FIGURE 4
Figure 4. LRIG3 and sLRIG3 inhibit migration and invasion of glioma cells. (A) Wound-healing assay of GL15, U87, and PriGBM cells overexpressing full-length LRIG3 and LRIG3 ectodomain proteins (sLRIG3). Representative images of wounded cell monolayers. Scale bar, 100 μm. (B) Quantification of healing areas of the different groups from each cell lines (Data represent the mean ± SD of triplicates from healing areas of one experiment. *p < 0.05; **p < 0.01 vs. control group; one-way ANOVA). (C) Invasion capacity as measured by transwell invasion assays. Representative images of the microscopic fields are shown. Scale bar, 50 μm. (D) Numbers of migrated cells per microscopic field were analyzed from five predetermined fields (Data represent the mean ± SD. *p < 0.05; **p < 0.01 vs. control group; one-way ANOVA).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: glioma, glioblastoma, LRIG3, soluble LRIG3, MET/PI3K/Akt pathway, prognosis
Citation: Cheng F, Zhang P, Xiao Q, Li Y, Dong M, Wang H, Kuang D, He Y, Duan Q, Mao F, Wang B and Guo D (2020) Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma. Front. Oncol. 10:591112. doi: 10.3389/fonc.2020.591112
Received: 04 August 2020; Accepted: 14 August 2020;
Published: 25 September 2020.
Edited and reviewed by: Thomas Daubon, UMR5095 Institut de Biochimie et Génétique Cellulaires (IBGC), France
Copyright © 2020 Cheng, Zhang, Xiao, Li, Dong, Wang, Kuang, He, Duan, Mao, Wang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Baofeng Wang, wbf620@163.com; Dongsheng Guo, guodongsheng@yahoo.com